{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:10:57Z","timestamp":1787890257564,"version":"build-2784847793"},"reference-count":41,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Hematology and Oncology"],"published-print":{"date-parts":[[2025,2,17]]},"DOI":"10.1080\/08880018.2024.2437047","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T12:05:41Z","timestamp":1733832341000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Tolerability of a 3-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients: Results of an Open-Label, Single-Arm Phase 4 Trial"],"prefix":"10.1080","volume":"42","author":[{"given":"Juan Luis","family":"Garcia Leon","sequence":"first","affiliation":[{"name":"Pediatric Oncology Service, Clinica Anglo Americana","place":["Lima, Peru"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"DiCristina","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruji","family":"Yao","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna Sadaf","family":"Afzal","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21631"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200003000-00009"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0b013e3182281493"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0994-7"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518765324"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26542"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30001"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.513970"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007301800"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.62"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.7859"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv482"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27690"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70061-6"},{"key":"e_1_3_5_17_1","unstructured":"US Federal Drug Administration. Clinical pharmacology review of EMEND for injection. US Federal Drug Administration. 2018;30. https:\/\/www.fda.gov\/media\/112698\/download. Accessed July 1 2022."},{"key":"e_1_3_5_18_1","unstructured":"European Medicines Agency. EMA EPAR assessment of EMEND. European Medicines Agency. Updated March. 2018;22.https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/ivemend-h-c-743-ii-0037-epar-assessment-report-variation_en.pdf. Accessed July 1 2022."},{"key":"e_1_3_5_19_1","unstructured":"EMEND (fosaprepitant) for injection for intravenous use. Merck & Co. Inc. Rahway NJ USA. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/e\/emend_iv\/emend_iv_lowedta_pi.pdf. Updated May 2022. Accessed September 9 2024."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958003-00018"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.01.023"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27646"},{"key":"e_1_3_5_23_1","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Washington DC. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Updated November 27 2017. Accessed November 2 2021."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1303"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13193"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-19.2.127"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27551"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6252-6"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21811"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11320"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds541"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00024669-200504010-00003"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs335"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11433"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl019"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04439-x"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S93620"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61024-1"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342070-00005"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2326-9"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.7706"},{"issue":"1","key":"e_1_3_5_42_1","first-page":"379","article-title":"Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens","volume":"35","author":"Fujii T","year":"2015","unstructured":"Fujii T, Nishimura N, Urayama KY, et\u00a0al. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens. Anticancer Res. 2015;35(1):379\u2013383.","journal-title":"Anticancer Res"}],"container-title":["Pediatric Hematology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08880018.2024.2437047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:29:37Z","timestamp":1740119377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/08880018.2024.2437047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,17]]}},"alternative-id":["10.1080\/08880018.2024.2437047"],"URL":"https:\/\/doi.org\/10.1080\/08880018.2024.2437047","relation":{},"ISSN":["0888-0018","1521-0669"],"issn-type":[{"value":"0888-0018","type":"print"},{"value":"1521-0669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipho20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipho20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}